An executive from the pharmaceutical organization GSK must select how much to amalgamate a freshly obtained biotechnology firm, Sirtris. Moncef Slaoui, GSK's worldwide head of R&D, championed the acquisition of Sirtris to gain access to its potentially ground-breaking science. Slaoui must balance the need to recoup shareholder value after paying a two times premium for Sirtris with his desire to retain Christoph Westphal, Sirtris's cofounder and CEO, and other key people at the company.
The case also explores the viewpoint of Christoph Westphal on the early hurdles of the impact GSK and the integration was having on Sirtris. This case can be exploited together with an additional case that ponders on Sirtris's business model.
PUBLICATION DATE: October 04, 2012 PRODUCT #: 813028-PDF-ENG
This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP
Related Case Solutions & Analyses:
David Melcher
General Dynamics and Computer Sciences Corp.: Outsourcing the IS Function (D)
American Barrick Resources Corp.: Managing Gold Price Risk
NEC
ABB Deutschland (A)
McCaw Cellular Communications Inc. (B)
Singapore TradeNet: The Tale Continues
Eastwind Trading Co. (C)
Saudi Arabia -SAGIA
Solving the Problems of New Product Forecasting
